Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
dc.contributor.author | Cathomas, R | |
dc.contributor.author | Crabb, S | |
dc.contributor.author | Mark, M | |
dc.contributor.author | Winterhalder, R | |
dc.contributor.author | Rothermundt, C | |
dc.contributor.author | Elliott, Tony | |
dc.contributor.author | Von Burg, P | |
dc.contributor.author | Kenner, H | |
dc.contributor.author | Hayoz, S | |
dc.contributor.author | Vilei, S | |
dc.contributor.author | Rauch, D | |
dc.contributor.author | Roggero, E | |
dc.contributor.author | Mohaupt, M | |
dc.contributor.author | Bernhard, J | |
dc.contributor.author | Manetsch, G | |
dc.contributor.author | Gillessen, S | |
dc.date.accessioned | 2016-10-12T12:13:55Z | |
dc.date.available | 2016-10-12T12:13:55Z | |
dc.date.issued | 2016-07-25 | |
dc.identifier.citation | Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). 2016: Prostate | en |
dc.identifier.issn | 1097-0045 | |
dc.identifier.pmid | 27457964 | |
dc.identifier.doi | 10.1002/pros.23236 | |
dc.identifier.uri | http://hdl.handle.net/10541/619937 | |
dc.description.abstract | We tested whether a switch maintenance treatment with orteronel, an oral inhibitor of androgen biosynthesis, prolongs disease control in men with metastatic castration-resistant prostate cancer (mCRPC) after documented disease stabilization with docetaxel. | |
dc.language | ENG | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to The Prostate | en |
dc.title | Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). | en |
dc.type | Article | en |
dc.contributor.department | Oncology/Hematology, Kantonsspital Graubunden, Chur, Switzerland | en |
dc.identifier.journal | The Prostate | en |
html.description.abstract | We tested whether a switch maintenance treatment with orteronel, an oral inhibitor of androgen biosynthesis, prolongs disease control in men with metastatic castration-resistant prostate cancer (mCRPC) after documented disease stabilization with docetaxel. |